Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Injection Speed and Site of Gantenerumab in Healthy Volunteers
NCT02882009Phase 1Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Local Pain as Assessed Using Visual Analog Scale. Started Aug 2016; status: completed.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02882009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882009.